entertainment -WSS

entertainment

author：explore 2025-09-27 19:28:48 - browse：48381

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Grad students accuse University of California of wage theft

focus

explore

WSS

As biotech industry slumps, bioscience job market is upside down

Fed up with FDA, ALS advocates consider a take

White House Covid adviser calls on docs to combat misinformation

Eli Lilly CEO gives to Mike Pence presidential super PAC

What happened to the House vote on health price transparency?

Assistant physicians can help address the primary care shortage

hotspot

entertainment

Wikipedia

Tori Bowie and the unacceptable rates of Black maternal death

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Cancer drug shortages should be causing more outrage

With clinical trial data readouts, here's how to spot spin

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Flagship Pioneering launches a new biotech in two countries

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Fed up with FDA, ALS advocates consider a take

Bright Health sells Medicare Advantage business to Molina

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

entertainment

U.K. Biobank has 500,000 peoples' genome sequences available

Fed up with FDA, ALS advocates consider a take

ReNAgade cuts staff seven months after raising $300 million

Diagnostic tests are hitting their mathematical limits

Senate bill would ban some hospital facility fees

CDC director unscathed in first congressional testimony

focus

explore

explore

explore